eloralintide vs cagrilintide Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Long-acting amylin-related peptides as therapies

Long acting amylin related peptides as therapies for obesity and type 2 diabetes ScienceDirect Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ScienceDirect Eloralintide GLP 1 83588 Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

SKU: 40297081473 · From equiscorp.hu